Good manufacturing practice production of CD34+ progenitor-derived NK cells for adoptive immunotherapy in acute myeloid leukemiaPaul K.J.D. de Jonge, Harry Dolstra, M. Foster et al.|Cancer Immunology Immunotherapy|2023Cited by 18
Preventive dendritic cell vaccination in healthy Lynch syndrome mutation carriersHarm Westdorp, I. Jolanda M. de Vries, Mark A.J. Gorris et al.|Annals of Oncology|2016Cited by 8
Good manufacturing practice production of an off-the-shelf CD34+ progenitor-derived NK cell product with preserved anti-tumor functionality post-infusion in NOD/SCID/IL2Rgnull miceLaura Hooijmaijers, Harry Dolstra, Marcos Vidal-Manrique et al.|Cellular and Molecular Life Sciences|2025Cited by 6
Intraperitoneal infusion of stem cell-derived natural killer cells in recurrent epithelial ovarian cancer patients: Results of the phase 1 INTRO-01 trialJanneke S. Hoogstad‐van Evert, Harry Dolstra, Paul K.J.D. de Jonge et al.|Gynecologic Oncology|2025Cited by 6